AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis
Author:
Funder
AstraZeneca
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health
Reference21 articles.
1. Cystic fibrosis;Ratjen;Nat Rev Dis Primers,2015
2. Assessment of the CFTR and ENaC association;Berdiev;Mol Biosyst,2009
3. Evidence for airway surface dehydration as the initiating event in CF airway disease;Boucher;J Intern Med,2007
4. Mucus clearance as a primary innate defense mechanism for mammalian airways;Knowles;J Clin Invest,2002
5. Bronchial mucus transport;Van der Schans;Respir Care,2007
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo;Journal of Cystic Fibrosis;2024-06
2. Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases;Israel Journal of Chemistry;2024-01-24
3. The Epithelial Sodium Channel—An Underestimated Drug Target;International Journal of Molecular Sciences;2023-04-24
4. Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation;American Journal of Physiology-Lung Cellular and Molecular Physiology;2022-11-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3